TrialAnnals of hematology2026

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Mario Ballerini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.